Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
BerGenBio ASA
Stanford University
Sumitomo Pharma America, Inc.
Case Comprehensive Cancer Center
Stanford University